ATE185271T1 - Behandlung von durch talgdrüse verursachten erkrankungen mit inhibitoren der acyl coa cholesterin acyltransferase - Google Patents

Behandlung von durch talgdrüse verursachten erkrankungen mit inhibitoren der acyl coa cholesterin acyltransferase

Info

Publication number: ATE185271T1
Authority: AT; Austria
Prior art keywords: diseases caused; acyl coa; coa cholesterol; inhibitors; treatment
Prior art date: 1994-08-31

Application number

AT95305594T

Other languages

English (en)

Inventor

James T Mayne

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-31

Filing date

1995-08-10

Publication date

1999-10-15

1995-08-10 Application filed by Pfizer filed Critical Pfizer

1999-10-15 Application granted granted Critical

1999-10-15 Publication of ATE185271T1 publication Critical patent/ATE185271T1/de

Links

102000001494 Sterol O-Acyltransferase Human genes 0.000 title abstract 4
108010054082 Sterol O-acyltransferase Proteins 0.000 title abstract 4
201000010099 disease Diseases 0.000 title abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
239000003112 inhibitor Substances 0.000 title abstract 3
210000001732 sebaceous gland Anatomy 0.000 title abstract 3
241001465754 Metazoa Species 0.000 abstract 3
208000015390 Sebaceous gland disease Diseases 0.000 abstract 2
230000002401 inhibitory effect Effects 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
229940002612 prodrug Drugs 0.000 abstract 2
239000000651 prodrug Substances 0.000 abstract 2
230000028327 secretion Effects 0.000 abstract 2
208000002874 Acne Vulgaris Diseases 0.000 abstract 1
206010000496 acne Diseases 0.000 abstract 1
125000002252 acyl group Chemical group 0.000 abstract 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Cosmetics (AREA)

AT95305594T 1994-08-31 1995-08-10 Behandlung von durch talgdrüse verursachten erkrankungen mit inhibitoren der acyl coa cholesterin acyltransferase ATE185271T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/298,735 US6133326A (en)	1994-08-31	1994-08-31	Compositions and methods for decreasing sebum production

Publications (1)

Publication Number	Publication Date
ATE185271T1 true ATE185271T1 (de)	1999-10-15

Family

ID=23151816

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95305594T ATE185271T1 (de)	1994-08-31	1995-08-10	Behandlung von durch talgdrüse verursachten erkrankungen mit inhibitoren der acyl coa cholesterin acyltransferase

Country Status (9)

Country	Link
US (2)	US6133326A (de)
EP (1)	EP0699439B1 (de)
JP (2)	JP3266473B2 (de)
AT (1)	ATE185271T1 (de)
CA (1)	CA2157142C (de)
DE (1)	DE69512589T2 (de)
DK (1)	DK0699439T3 (de)
ES (1)	ES2136252T3 (de)
GR (1)	GR3031917T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6080408A (en) *	1994-08-22	2000-06-27	Connaught Laboratories Limited	Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
KR20010099975A (ko) *	1998-12-28	2001-11-09	우에하라 아끼라	외용제
US20030077301A1 (en) *	1999-12-16	2003-04-24	Maibach Howard I.	Topical pharmaceutical composition for the treatment of inflammatory dermatoses
KR20020073574A (ko)	2000-02-02	2002-09-27	워너-램버트 캄파니	피지선 장애 치료용 콜레스테롤 에스테르 및 왁스에스테르 합성 이중 억제제
IL159156A0 (en) *	2001-06-22	2004-06-01	Millard Marsden Mershon	A gel forming composition containing a polyacrylic acid
EP1281399A3 (de) *	2001-08-01	2004-02-11	Warner-Lambert Company	Hemmer mit doppelter Wirkung auf Wachsester- und Cholesterylestersynthese zur Hemmung der Sebumproduktion
JP2005526063A (ja) *	2002-03-12	2005-09-02	ガルデルマ・リサーチ・アンド・デヴェロップメント・エス・エヌ・セ	皮膚疾患を治療するためのアダパレンの使用
JP2005060386A (ja) *	2003-07-29	2005-03-10	Rohto Pharmaceut Co Ltd	皮膚外用剤
JP2009102358A (ja) *	2003-07-29	2009-05-14	Rohto Pharmaceut Co Ltd	皮膚外用剤
RU2342930C2 (ru)	2003-10-09	2009-01-10	Уорнер-Ламберт Компани Ллс	Фармацевтические композиции, содержащие малонамидные производные для уменьшения продукции кожного сала
MX2007010374A (es) *	2005-02-24	2007-09-25	Warner Lambert Co	Inhibidor de acat cristalino.
FR2918890A1 (fr) *	2007-07-19	2009-01-23	Galderma Res & Dev	Utilisation du pactimibe pour la preparation d'un medicament destine a prevenir ou a traiter une maladie due a un dysfonctionnement des glandes sebacees chez l'homme ou l'animal
FR2918889B1 (fr) *	2007-07-19	2009-10-23	Galderma Res & Dev	Utilisation de l'eflucimibe pour la preparation d'un medicament destine a prevenir ou a traiter une maladie due a un dysfonctionnement des glandes sebacees chez l'homme ou l'animal
FR2920771B1 (fr) *	2007-09-06	2009-10-30	Galderma Res & Dev	Nouveaux derives de phenylurees, inhibiteurs de l'enzymes soat-1, compositions pharmaceutiques et cosmetiques les contenant
FR2920769B1 (fr)	2007-09-06	2009-10-30	Galderma Res & Dev	Nouveaux derives de n-phenyl acetamide, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant
CN101502541B (zh) *	2008-02-04	2011-12-28	成都地奥九泓制药厂	安息香属植物及其提取物的用途
FR2946345B1 (fr)	2009-06-05	2011-05-20	Galderma Res & Dev	Nouveaux derives dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
FR2946346B1 (fr)	2009-06-05	2011-05-20	Galderma Res & Dev	Nouveaux derives dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
FR2946342B1 (fr)	2009-06-05	2011-06-24	Galderma Res & Dev	Nouveaux derives de dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
FR2946340B1 (fr)	2009-06-05	2011-06-24	Galderma Res & Dev	Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
EP3463277A4 (de)	2016-06-06	2020-01-01	GDD Therapeutics, LLC	Formulierungen für substituierte 3-pyrrolidine, zusammensetzungen damit und verwendungen davon

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3729568A (en)	1969-09-23	1973-04-24	Johnson & Johnson	Acne treatment
US4302456A (en) *	1977-04-13	1981-11-24	The Upjohn Company	Process for therapeutic treatment
US4514385A (en) *	1981-10-05	1985-04-30	Alcon Laboratories, Inc.	Anti-acne compositions
EP0170105B1 (de)	1984-07-07	1990-10-17	Koichi Prof. Dr. Shudo	Benzoesäurederivate
LU86258A1 (fr)	1986-01-21	1987-09-03	Rech Dermatologiques C I R D S	Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US4751026A (en)	1986-03-24	1988-06-14	Warner-Lambert Company	Substituted anilides of oleic, linoleic, or linolenic acid as inhibitors of acyl-coa:cholesterol acyltransferase
US4722927A (en)	1986-04-28	1988-02-02	Warner-Lambert Company	Pyrimidine amides of oleic or linoleic acid, composition containing them and their use as inhibitors of acyl-CoA cholesterol acyltransferase
JPS6323848A (ja)	1986-07-11	1988-02-01	ワ−ナ−−ランバ−ト・コンパニ−	Ω−（置換フエニルオキシ）−アルカン酸のアリ−ル−およびアラルキルアミド
US4716175A (en) *	1987-02-24	1987-12-29	Warner-Lambert Company	Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase
US4743605A (en)	1987-02-24	1988-05-10	Warner-Lambert Company	Saturated fatty acid amides as inhibitors of acyl-coa:cholesterol acyltransferase
US5015644A (en)	1987-06-02	1991-05-14	Warner-Lambert Company	Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
IE61716B1 (en)	1987-06-02	1994-11-30	Warner Lambert Co	Antihyperlipidemic and antiatherosclerotic urea compounds
ES2037768T3 (es)	1987-07-02	1993-07-01	Warner-Lambert Company	Procedimiento para preparar n-(fenil(2,6-disustituido))-ureas y carbamatos inhibidores de acil-coa: colesterol acil-transferasa.
US4868210A (en)	1988-03-30	1989-09-19	Warner-Lambert Company	Antihyperlipidemic and antiatherosclerotic compounds and compositions
US5116848A (en)	1988-03-30	1992-05-26	Warner-Lambert Company	N-(((2,6-disubstituted)phenyl)-n-diarylalkyl)ureas as antihyperlipidemic and antiatherosclerotic agents
US5155127A (en)	1989-02-09	1992-10-13	Warner-Lambert Company	N-(substituted aryl)-n'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents
US4994465A (en) *	1989-02-17	1991-02-19	Warner-Lambert Company	Antihyperlipidemic and antiatherosclerotic trisubstituted urea compounds
US5204093A (en) *	1989-04-06	1993-04-20	Victor Steven A	Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same
AU632809B2 (en)	1989-05-25	1993-01-14	Takeda Chemical Industries Ltd.	Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
CA2022346A1 (en)	1989-08-04	1991-02-05	Mitsubishi Chemical Corporation	1-phenylalkyl-3-phenylurea derivatives
WO1991004027A1 (en)	1989-09-15	1991-04-04	Pfizer Inc.	New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
TW205037B (de)	1989-10-06	1993-05-01	Takeda Pharm Industry Co Ltd
JPH05310678A (ja)	1990-01-22	1993-11-22	Mitsubishi Kasei Corp	１−フェニルアルキル−３−フェニル尿素誘導体
WO1993015058A1 (en) *	1992-01-23	1993-08-05	Pfizer Inc.	4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
EP0642498A1 (de) *	1992-05-28	1995-03-15	Pfizer Inc.	N-aryl und n-heteroaryl derivate als acat-hemmstoffe
US5902805A (en) *	1996-04-22	1999-05-11	L'oreal	Method for treatment of acne and/or the effects of ageing using HMG-coenzyme A-reductase inhibitor and compositions for performing the same
US5965553A (en) *	1996-06-20	1999-10-12	Pfizer Inc.	Squalene synthetase inhibitors
US5834480A (en) *	1997-06-13	1998-11-10	Elkhoury; George F.	Topical application of opioids for treatment of acne and sebaceous gland disorders
US5994330A (en) *	1998-11-09	1999-11-30	El Khoury; Georges F.	Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions
US9206485B2 (en)	2011-08-19	2015-12-08	J. Edwin Roy	Portable sugar mill
US9303539B1 (en)	2012-06-10	2016-04-05	Ags I-Prop, Llc	Universal drain plug system and method
US9210886B2 (en)	2014-03-27	2015-12-15	Monsanto Technology Llc	Plants and seeds of corn variety CV410274

1994
- 1994-08-31 US US08/298,735 patent/US6133326A/en not_active Expired - Fee Related
1995
- 1995-08-10 EP EP95305594A patent/EP0699439B1/de not_active Expired - Lifetime
- 1995-08-10 ES ES95305594T patent/ES2136252T3/es not_active Expired - Lifetime
- 1995-08-10 DE DE69512589T patent/DE69512589T2/de not_active Expired - Lifetime
- 1995-08-10 AT AT95305594T patent/ATE185271T1/de not_active IP Right Cessation
- 1995-08-10 DK DK95305594T patent/DK0699439T3/da active
- 1995-08-29 JP JP24229795A patent/JP3266473B2/ja not_active Expired - Lifetime
- 1995-08-29 CA CA002157142A patent/CA2157142C/en not_active Expired - Lifetime
1999
- 1999-11-19 GR GR990403007T patent/GR3031917T3/el unknown
2000
- 2000-03-27 US US09/536,480 patent/US6271268B1/en not_active Expired - Lifetime
2001
- 2001-08-09 JP JP2001241766A patent/JP2002053494A/ja active Pending

Also Published As

Publication number	Publication date
EP0699439B1 (de)	1999-10-06
US6271268B1 (en)	2001-08-07
ES2136252T3 (es)	1999-11-16
GR3031917T3 (en)	2000-03-31
JP2002053494A (ja)	2002-02-19
EP0699439A3 (de)	1996-06-26
DE69512589D1 (de)	1999-11-11
CA2157142C (en)	1998-06-09
CA2157142A1 (en)	1996-03-01
EP0699439A2 (de)	1996-03-06
US6133326A (en)	2000-10-17
DE69512589T2 (de)	2000-01-27
JPH0899903A (ja)	1996-04-16
JP3266473B2 (ja)	2002-03-18
DK0699439T3 (da)	1999-12-27

Legal Events

Date	Code	Title	Description
2000-03-15	UEP	Publication of translation of european patent specification
2010-05-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69512589D1 (de)	1999-11-11	Behandlung von durch Talgdrüse verursachten Erkrankungen mit Inhibitoren der Acyl CoA Cholesterin Acyltransferase
DE69636342D1 (de)	2006-08-24	Liponsäure in topischen mittel
UY25322A1 (es)	2004-07-30	Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
DE69939651D1 (de)	2008-11-13	Behandlung hyperproliferativer erkrankungen
BR9809115A (pt)	2002-01-02	Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt
ATE173630T1 (de)	1998-12-15	Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren
PT971713E (pt)	2003-09-30	Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
EA199900137A1 (ru)	1999-06-24	Замещенные пиридины в качестве избирательных ингибиторов циклооксигеназы-2
ATE209483T1 (de)	2001-12-15	Behandlung von multipler sklerose
GEP20033044B (en)	2003-08-25	Method for Treating Atherosclerosis
CA2002859A1 (en)	1990-05-29	Method of treating epithelial disorders
BR9712792A (pt)	1999-12-14	Inibidores de metaloprotease bidentada.
WO1992019617A3 (en)	1992-12-10	Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
RU94044453A (ru)	1996-10-10	Применение 2-фенил-3-ароилбензотиофенов для ингибирования себореи и угрей
ATE212837T1 (de)	2002-02-15	Pharmazeutische zubereitung zur behandlung akuter rhinitiden, enthaltend sympthomimeticum und pantothenol und/oder pantothensäure
ES2106531T3 (es)	1997-11-01	Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
EA199800717A1 (ru)	1999-02-25	Способ лечения заболеваний млекопитающих и цвиттерионная композиция
CZ63295A3 (en)	1995-11-15	1 alpha-fluoro-25-hydroxy-16-en-23-in-cholecalciferol as such and for the use as a therapeutic active compound, its use for the preparation of a pharmaceutical preparation, process of its preparation and a pharmaceutical preparation based thereon
BR0110396A (pt)	2003-07-01	Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
DE69736945D1 (de)	2006-12-28	Biphenylverbindungen sowie ihre anwendung als östrogene mittel
DE69818823D1 (de)	2003-11-13	Dipohosphonsäuresalze für die behandlung von osteoporose
DE69822626D1 (de)	2004-04-29	Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
NO971743L (no)	1997-04-16	Farmasöytisk sammensetning for profylakse og behandling av type I allergiske sykdommer
BR0107954A (pt)	2002-10-22	Inibidores duplos de sìntese de éster de colesterol e éster de cera para distúrbios de glândula sebácea
NO923198L (no)	1993-02-16	Terapeutiske midler